Amgen Inc. (AMGN)
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Here's Why Amgen (AMGN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Amgen (AMGN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amgen: Waiting Patiently For A Real Catalyst
Amgen Inc.'s diversified portfolio ensures steady revenue but modest growth, with no single drug contributing more than 15% to total revenue. Recent revenue growth and margin upticks are promising, but sustainability remains uncertain amid biosimilar competition and pricing pressures. High debt levels and slow deleveraging, particularly from the Horizon Therapeutics acquisition, pose risks to future M&A and capital efficiency.
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales Growth
AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.
Amgen: Reducing My Price Target, Reiterate Buy After A Solid Q1
Amgen reported strong Q1 results with a 9% YoY revenue increase and a 24% rise in operating EPS, but shares dipped due to risk-on market sentiment. Despite competitive pressures and softer EPS trends, Amgen remains undervalued with a high dividend yield of 3.39% and robust free cash flow. Key risks include emerging therapies and macroeconomic factors, but positive Phase III data and new product launches support a buy-the-dip strategy.
Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth
AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.
Amgen Inc. (AMGN) Q1 2025 Earnings Call Transcript
Amgen Inc. (NASDAQ:AMGN ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Commercial Operations James Bradner - EVP, Research & Development Peter Griffith - EVP & CFO Conference Call Participants Terence Flynn - Morgan Stanley Salveen Richter - Goldman Sachs Michael Yee - Jefferies Trung Huynh - UBS Evan Seigerman - BMO Capital Markets Chris Schott - JPMorgan Yaron Werber - TD Cowen Umer Raffat - Evercore ISI David Amsellem - Piper Sandler Jay Olson - Oppenheimer Gregory Renza - RBC Capital Markets Matt Phipps - William Blair Alex Hammond - Wolfe Research Operator My name is Julianne and I'll be your conference facilitator today for the Amgen Q1 FY 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
Compared to Estimates, Amgen (AMGN) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amgen (AMGN) Tops Q1 Earnings and Revenue Estimates
Amgen (AMGN) came out with quarterly earnings of $4.90 per share, beating the Zacks Consensus Estimate of $4.16 per share. This compares to earnings of $3.96 per share a year ago.
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
